Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study

Séverine Guiu,Laurent Arnould,Franck Bonnetain,Cécile Dalban,Laure Favier,Isabelle Desmoulins,Gilles Créhange,Charles Coutant,Pierre Fumoleau,Bruno Coudert
DOI: https://doi.org/10.1016/j.breast.2012.07.012
IF: 4.254
2013-06-01
The Breast
Abstract:PURPOSE OF THE RESEARCH: HER2-positive and triple-negative breast cancer (TNBC) still have a poor prognosis. Pathological complete response (pCR) is usually considered a surrogate marker for outcome. The aim of this study was to reconsider these parameters on a large population after a long follow-up. 348 patients with unilateral breast cancer who received neoadjuvant treatment at our institution over 30 years were included.RESULTS: Patients were classified according to hormonal receptors (HR) and HER2. Median follow-up was 7 years. pCR was significantly lower in HR+/HER2- tumors (P < 0.0001). The 7-year OS rates were 76.1% (HR+/HER2-), 60.1% (TNBC), 72.4% (HR+/HER2+), and 49.9% (HR-/HER2+). Disease-free survival (DFS) and OS differed significantly according to pCR. Among HER2+ patients, pCR rate, DFS and OS were greater with trastuzumab.CONCLUSIONS: TNBC and HR-/HER2+ tumors have the worst outcome. pCR remains a significant prognostic factor. Trastuzumab strongly improves pCR and survival in HER2+ tumors.
oncology,obstetrics & gynecology
What problem does this paper attempt to address?